pharmaphorum December 9, 2024
Legislation in the US that could have a dramatic impact on the businesses of five biotechs with links to China has been left out of a key bill, introducing a delay that will likely extend into the next administration.
The BIOSECURE Act, which will prohibit businesses in the US from contracting with various Chinese firms on national security grounds, has not been included in a defence budget bill viewed as probably the last chance to pass the bill in 2024 before Congress goes on recess.
In its current form, the BIOSECURE Act would prohibit the federal government from contracting with, or providing grants to, companies that do business with a “biotechnology company of concern.” It specifically mentions five biotechs –...
Today's Sponsors
Today's Sponsor